Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi ...

Image Source: Zacks Investment Research Nexletol and Nexlizet are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka ...

Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.